CONSHOHOCKEN, Pa., June 04, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. MDGL today announced that Paul Friedman, M.D., Chief Executive Officer of Madrigal, and Becky Taub, M.D., CMO and Executive VP, Research & Development of Madrigal will present at the following conferences in June 2019:
Jefferies 2019 Healthcare Conference – New York
Thursday - June 6, 2019, 10:00 AM ET
Goldman Sachs 40th Annual Global Healthcare Conference - Rancho Palos Verdes, CA,
Wednesday, June 12, 2019, 11:20 AM PT
JMP Securities Life Sciences Conference – New York
Wednesday, June 19, 2019, 3:30 PM ET
Live webcasts of the presentations can be accessed through the Investors section of the Madrigal website at https://www.madrigalpharma.com
A replay of the webcasts will be available for 90 days following the live presentations.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. MDGL is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. Madrigal's lead candidate, resmetirom, is a first-in- class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR)-β selective agonist.
For more information, please visit www.madrigalpharma.com.
Investor Contact:
Marc Schneebaum, Madrigal Pharmaceuticals, Inc. IR@madrigalpharma.com
Media Contact:
Mike Beyer, Sam Brown Inc. mikebeyer@sambrown.com 312 961 2502
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.